Search Weight Loss Topics:




May 4

ViroPharma Announces Upcoming Data Presentation Of Plenadren® (Hydrocortisone, Modified Release Tablet) At 2012 Joint …

Long Term Weight Loss Comments Off on ViroPharma Announces Upcoming Data Presentation Of Plenadren® (Hydrocortisone, Modified Release Tablet) At 2012 Joint …

EXTON, Pennsylvania, May 3, 2012 /PRNewswire/ -- ViroPharma Incorporated announced three posters will be presented relating to long term data on Plenadren (hydrocortisone, modified release tablet) on May 7 at the 2012 joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology (ICE/ECE), held May 5 through 9, in Florence, Italy.

Embargo Lifts on Monday, May 7, at 00:01 hours local Florence time.

Poster Presentations

Poster ID: #78 Presenter: Anna Nilsson Title: An Open, Multi-Centre, Phase IIIb, Long-Term Follow-up Study to Assess the Safety, Tolerability and Efficacy of Once-Daily Oral Dual-Release Hydrocortisone in Patients with Adrenal Insufficiency Time: 18:00 - 19:30 hours local Florence time Location: Padiglione Spadolini - Attico at Fortezza da Basso Link: http://www.endocrine-abstracts.org/ea/0029/ea0029p78.htm [http://www.endocrine-abstracts.org/ea/0029/ea0029p78.htm]

Poster ID: #P50 Presenter: Gudmundur Johannsson Title: Intercurrent Illness Dose Regimen in Adrenal Insufficiency with a Dual-Release Hydrocortisone Formulation Derived from Population Pharmacokinetic Modeling Time: 18:00 - 19:30 hours local Florence time Location: Padiglione Spadolini - Attico at Fortezza da Basso Link: http://www.endocrine-abstracts.org/ea/0029/ea0029p50.htm [http://www.endocrine-abstracts.org/ea/0029/ea0029p50.htm]

Poster ID: #P76 Presenter: Maria Forss Title: Dosing Regimens for Glucocorticoid Replacement Therapy - A Worldwide Patient Survey of Patients with Adrenal Insufficiency Time: 18:00 - 19:30 hours local Florence time Location: Padiglione Spadolini - Attico at Fortezza da Basso Link: http://www.endocrine-abstracts.org/ea/0029/ea0029p76.htm [http://www.endocrine-abstracts.org/ea/0029/ea0029p76.htm]

About Plenadren (hydrocortisone, modified release tablet)

Plenadren is indicated for the treatment of adrenal insufficiency in adults.

Hypersensitivity to the active substance of Plenadren or to any of the excipients may occur. During acute adrenal insufficiency, parenteral administration of hydrocortisone in high doses, together with physiological sodium chloride solution for injection, must be given. Use of Plenadren with potent CYP 3A4 inducers and inhibitors may merit an adjustment of hydrocortisone dosage. High (supra-physiological) dosages of cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. Long-term treatment with higher than physiological hydrocortisone doses can lead to clinical features resembling Cushings syndrome with increased adiposity, abdominal obesity, hypertension and diabetes, and thus result in an increased risk of cardiovascular morbidity and mortality. All glucocorticoids increase calcium excretion and reduce the bone remodeling rate. Patients with adrenal insufficiency on long term glucocorticoid replacement therapy have been found to have reduced bone mineral density. Psychiatric adverse events may occur with systemic glucocorticoids.

The most common adverse reactions observed in clinical studies have been fatigue, gastroenteritis, upper respiratory tract infection, sedation, vertigo and dry eyes.

Read more from the original source:
ViroPharma Announces Upcoming Data Presentation Of Plenadren® (Hydrocortisone, Modified Release Tablet) At 2012 Joint ...

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker